Detalles de la búsqueda
1.
Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysis.
BMC Cancer
; 22(1): 992, 2022 Sep 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36115960
2.
Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial.
Int J Cancer
; 145(1): 295-305, 2019 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30613964
3.
Prognosis of Fibrosarcoma in Patients With and Without a History of Radiation for Nasopharyngeal Carcinoma.
Ann Surg Oncol
; 24(2): 434-440, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27654106
4.
Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
Jpn J Clin Oncol
; 47(8): 683-689, 2017 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28453815
5.
Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.
Lancet Oncol
; 17(11): 1509-1520, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27686945
6.
Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?
Ann Surg Oncol
; 23(1): 273-81, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26215200
7.
Epidermal Growth Factor Receptor Mutation Status and Treatment Outcome for R0-Resected Patients with Stage 3 Non-small Cell Lung Cancer.
Ann Surg Oncol
; 23(6): 2115-22, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26887852
8.
Association of insulin-like growth factor-binding protein-3 with radiotherapy response and prognosis of esophageal squamous cell carcinoma.
Chin J Cancer
; 34(11): 514-21, 2015 Sep 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-26370590
9.
Dosimetric benefit to organs at risk following margin reductions in nasopharyngeal carcinoma treated with intensity-modulated radiation therapy.
Chin J Cancer
; 34(5): 189-97, 2015 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-26058563
10.
Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China.
Cancer
; 119(12): 2230-8, 2013 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23576020
11.
Assessing the role of volumetric-modulated arc therapy in hepatocellular carcinoma.
J Appl Clin Med Phys
; 14(3): 4162, 2013 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-23652248
12.
[Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients with ypT1-4N0 after neo-adjuvant chemoradiotherapy].
Zhonghua Zhong Liu Za Zhi
; 35(9): 708-13, 2013 Sep.
Artículo
en Zh
| MEDLINE | ID: mdl-24332061
13.
[Retrospective analysis of effectiveness of intensity-modulated radiotherapy combined with chemotherapy or not for locoregionally advanced nasopharyngeal carcinoma].
Zhonghua Yi Xue Za Zhi
; 93(29): 2292-5, 2013 Aug 06.
Artículo
en Zh
| MEDLINE | ID: mdl-24300148
14.
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Lancet Oncol
; 13(2): 163-71, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22154591
15.
Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3.
J Transl Med
; 10: 249, 2012 Dec 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-23232108
16.
The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin.
Tumour Biol
; 33(4): 1115-23, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22389159
17.
[A multi-centered randomized controlled study of neo-adjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of esophagus: an interim analysis].
Zhonghua Yi Xue Za Zhi
; 92(15): 1028-32, 2012 Apr 17.
Artículo
en Zh
| MEDLINE | ID: mdl-22781642
18.
Progression-free survival at 3 years is a reliable surrogate for 5-year overall survival for patients suffering from locally advanced esophageal squamous cell carcinoma.
Cancer Med
; 11(20): 3751-3760, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35434962
19.
Overexpression of eIF5A-2 is an adverse prognostic marker of survival in stage I non-small cell lung cancer patients.
Int J Cancer
; 129(1): 143-50, 2011 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20830705
20.
High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.
Int J Cancer
; 127(1): 138-47, 2010 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19904743